利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。

Objectives: - Understand the stages of vascular adverse events related to filler in darker skin types

- Remark how injection anatomy and complications can be made visible through facial ultrasound

- Learn the principles of ultrasound guided hyaluronidase injection to treat vascular adverse events

Introduction: A 41y old female patient Fitzpatrick photo type 5 presented 3 days after chin augmentation with hyaluronic acid-based filler with a vascular adverse event at skin ischemia stage 3-4. One day after initial treatment, quarantine was obligatory due to COVID 19 infection with severe symptoms.

Materials / method: A watch and wait approach, 1g of aspirin and tissue warming was decided due to impossibility to asses. Clinical assessment took place 5 days after treatment and negative COVID test, a stage 5 skin ischemia was diagnosed with local vasospasm of the superficial chin fibro-fatty layer via ultrasound. Dissolving via us-guided low-dose hyaluronidase injection (Schelke Protocol) released the vasospasm as well as the pain and pressure immediately, the blood flow was increased in the us-duplex imaging. Wound care and early-induced multimodal scar therapy was performed.

Results: After all, the patient shows minimal scarring and hyperpigmentation, the outcome of the chin augmentation was not influenced, no re-treatment was needed.

Conclusion: Early diagnosis of vascular adverse events is particularly challenging in individuals with darker skin tones due to the subtler skin changes observed during the initial stages of skin ischemia.

Even after presentation at late stage of skin ischemia, ultrasound targeted hyaluronidase infiltration helped to restore the blood flow, release pain and pressure and avoid severe scarring.

The management of vascular adverse events using ultrasound allows for precise diagnosis and the precise administration of low-dose hyaluronidase injections.

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
是
请注明名称（个人，公司，学会等等）: augmented anatomy

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
是
请注明名称（个人，公司，学会等等）: trainer and partner cutaneous

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。